SCHEMBL1744362

SCHEMBL1744362

CCCCCCCCCCCCOC(=O)C(C)NC(C)C(=O)OCCCCCCCCCCCC

nearest known ligand 0.58

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.55
NAAA Q02083 1/20 0.53
FAAH O00519 1/20 0.49
ACHE P22303 6/20 0.48
TSHR P16473 3/20 0.48
ZDHHC7 Q9NXF8 1/20 0.47
HCAR2 Q8TDS4 1/20 0.46
RAD52 P43351 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
ALDH1A1 P00352 1/20 0.44
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL116383 1.00 EPHX1 (0.55) EPHX1NAAAFAAHACHETSHR
SCHEMBL15796303 0.92 EPHX1 (0.52) EPHX1NAAAFAAHACHETSHR
SCHEMBL18510017 0.92 ALDH1A1 (0.52) EPHX1NAAAACHETSHRZDHHC7
SCHEMBL18510055 0.92 ALDH1A1 (0.52) EPHX1NAAAACHETSHRZDHHC7
SCHEMBL851835 0.91 EPHX1 (0.47) EPHX1NAAAFAAHACHETSHR
SCHEMBL851488 0.91 EPHX1 (0.47) EPHX1NAAAFAAHACHETSHR
Hydrochloric Acid SCHEMBL15569070 0.91 EPHX1 (0.50) EPHX1NAAAFAAHACHETSHR
SCHEMBL593216 0.90 EPHX1 (0.46) EPHX1NAAAFAAHACHETSHR
SCHEMBL16929671 0.87 EPHX1 (0.46) EPHX1NAAAFAAHACHETSHR
SCHEMBL15796558 0.86 EPHX1 (0.58) EPHX1NAAAFAAHACHETSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12473379-B2 Method for obtaining purified bacterial polysaccharides SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) 2025-11-18 US claimed
CN-113101300-A Medical device for preventing and/or treating infection of skin injury 法斯特麦德意大利有限公司 2021-07-13 CN claimed
US-20210070890-A1 METHOD FOR OBTAINING PURIFIED BACTERIAL POLYSACCHARIDES SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) 2021-03-11 US claimed
EP-3789494-A1 METHOD FOR OBTAINING PURIFIED BACTERIAL POLYSACCHARIDES Serum Institute of India Private Limited (IN) 2021-03-10 EP claimed
EP-2436700-B1 SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULAR STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES WYETH LLC (US) 2018-06-20 EP claimed
CN-106398306-A Pigment preparing product used for acrylon stock solution dying, and preparation method thereof 苏州世名科技股份有限公司 2017-02-15 CN claimed
EP-2129693-B1 SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULAR STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES WYETH LLC (US) 2016-12-07 EP claimed
CN-104994864-A Stable aqueous composition comprising human insulin or an analogue or derivative thereof WOCKHARDT LTD 2015-10-21 CN claimed
US-8999697-B2 Shortened purification process for the production of capsular Streptococcus pneumoniae polysaccharides WYETH LLC (US) 2015-04-07 US claimed
US-20140363463-A1 SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULAR STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES WYETH LLC (US) 2014-12-11 US claimed
EP-2129693-A2 SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULARSTREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES Wyeth (US) 2009-12-09 EP claimed
US-20080286838-A1 SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULAR STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES WYETH (US) 2008-11-20 US claimed
WO-2008118752-A2 SHORTENED PURIFICATION PROCESS FOR THE PRODUCTION OF CAPSULAR STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDES WYETH (US) 2008-10-02 WO claimed
US-12473379-B2 Method for obtaining purified bacterial polysaccharides SERUM INSTITUTE OF INDIA PRIVATE LIMITED (IN) 2025-11-18 US disclosed
US-12343389-B2 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof PFIZER INC. (US) 2025-07-01 US disclosed
US-20250163484-A1 Methods for Incorporating Azido Groups in Bacterial Capsular Polysaccharides PFIZER (US) 2025-05-22 US disclosed
WO-2000044864-A1 BAR COMPOSITIONS CONTAINING SOLID AMPHOTERIC SURFACTANTS UNILEVER PLC (GB) 2000-08-03 WO disclosed
US-5786319-A LIQUID DETERGENT COMPRISING GLYCOL ETHER SOLVENT SYSTEM, NONIONIC SURFACTANT, HYDROTROPE STABLY DISPERSED IN WATER DIVERSEY LEVER, INC. (US) 1998-07-28 US disclosed
EP-0840778-A1 CONCENTRATED AQUEOUS DEGREASING CLEANSER UNILEVER N.V. (NL) 1998-05-13 EP disclosed
WO-1997004069-A1 CONCENTRATED AQUEOUS DEGREASING CLEANSER UNILEVER N.V. (NL) 1997-02-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12343389-B2 Streptococcus pneumoniae capsular polysaccharides and conjugates thereof STT3B, VGF, STT3A EPHX1 4613/4885NAAA 2379/4885FAAH 4861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.